Skip to main content

A18-00 / ENGOT-CX11 A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18/ENGOT-cx11/GOG-3047)

NCT04221945

A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18/ENGOT-cx11/GOG-3047)

Associated Conditions

Cervical Cancer

Principal Investigator

Sponsor

Merck Sharp & Dohme

The purpose of this study is to: (a) Test the safety of the study drug, pembrolizumab, when given with chemoradiotherapy; (b) See if pembrolizumab, when given with chemoradiotherapy, controls cancer better than chemoradiotherapy alone; (c) See if pembrolizumab, when given with chemoradiotherapy, helps patients live longer, compard to chemoradiotherapy alone; (d) See if pembrolizumab, when given with chemoradiotherapy, helps patients have a better quality of life, compared to chemoradiotherapy alone; and (e) See how well participants tolerate pembrolizumab given with chemoradiotherapy.

This study is currently enrolling.